Last reviewed · How we verify
Neuronox(R)
Neuronox is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.
Neuronox is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Neuronox(R) |
|---|---|
| Also known as | Intramuscular injection |
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (acetylcholine release machinery) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | Phase 3 |
Mechanism of action
Neuronox works by cleaving SNARE proteins required for acetylcholine vesicle fusion and release at the neuromuscular junction. This results in temporary paralysis of targeted muscles, reducing involuntary contractions and muscle hyperactivity. The effect is localized to injected muscles and gradually reverses over 3-4 months as new neuromuscular junctions form.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Wrinkle reduction (cosmetic use)
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness in adjacent muscles
- Ptosis (eyelid drooping)
- Dry mouth
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuronox(R) CI brief — competitive landscape report
- Neuronox(R) updates RSS · CI watch RSS
- Department of Medical Services Ministry of Public Health of Thailand portfolio CI